首页> 外文期刊>Clinical proteomics. >Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry
【24h】

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry

机译:靶向人脑脊髓液中的灯2,具有免疫耐压和高分辨率平行反应监测质谱法的组合

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Alzheimer's disease is the most common form of dementia. An increasing body of evidence suggests that endo-lysosomal dysfunction is a pathogenic mechanism of Alzheimer's disease. Thus there is a potential for proteins involved in the normal function of endo-lysosomal vesicles to act as biomarkers of disease. Herein we focused on the lysosomal protein LAMP2 that is involved in chaperone mediated autophagy. Results: Using a combination of immunoprecipitation, digestion and nano-liquid chromatography tandem mass spectrometry we targeted and identified six tryptic LAMP2 peptides in human cerebrospinal fluid. Employing the identified proteotypic tryptic peptides a hybrid immunoprecipitation high resolution parallel reaction monitoring mass spectrometric method was developed for the relative quantitation of LAMP2. The method was evaluated in a number of experiments which defined the overall methodological as well as the analytical micro-liquid chromatography mass spectrometric intra- And inter-day variability. We identified an overall methodological peptide dependent intra-day variability of 8-16 %. The inter-day experiments showed similar results. The analytical contribution to the variation was minor with a coefficient of variation of 0.5-2.1 %, depending on the peptide. Using the developed method, with defined and limited variability, we report increased cerebrospinal fluid levels of three LAMP2 peptides in Alzheimer's disease subjects (n = 14), as compared to non-Alzheimer's disease controls (n = 14). Conclusion: Altered LAMP2 levels in cerebrospinal fluid may indicate endo-lysosomal dysfunction in Alzheimer's disease. However, further studies in larger cohorts comprised of well-defined patient materials are required. We here present a tool which can be used for exploring the relevance of the level of LAMP2 as a potential measure of lysosomal dysfunction in Alzheimer's disease or other neurodegenerative diseases.
机译:背景:阿尔茨海默病是最常见的痴呆形式。越来越多的证据表明,内冬溶血剂功能障碍是阿尔茨海默病的一种致病机制。因此,存在蛋白质的蛋白质涉及内部溶酶体囊泡的正常功能,以充当疾病的生物标志物。在此,我们专注于涉及伴随伴侣介导的自噬的溶酶体蛋白灯2。结果:使用免疫沉淀,消化和纳米液相色谱的组合串联质谱仪我们靶向并鉴定了人脑脊髓液中的六个胰蛋白灯2肽。采用鉴定的蛋白质胰蛋白酶肽杂交免疫沉淀高分辨率高分辨率平行反应监测质谱法,用于灯2的相对定量。在多种实验中评价该方法,该实验中定义了整体方法论以及分析微液相色谱质谱内和日间变异性。我们鉴定了总体方法肽依赖性蛋白质依赖性血小肽,其内变异性为8-16%。日内的实验表现出类似的结果。根据肽,对变异的分析贡献是较小的0.5-2.1%的变异系数。使用明确和有限的可变性的方法,与非阿尔茨海默病对照(n = 14)相比,我们报告了阿尔茨海默病受试者(n = 14)中的三个灯2肽的增加脑脊液水平。结论:脑脊液中的改变灯2水平可能表明阿尔茨海默病患者的内泌体血糖功能障碍。然而,需要在较大的群组中进行进一步的研究,包括由明确定义的患者材料。我们在这里提出一种工具,可用于探索灯泡2水平的相关性作为阿尔茨海默病或其他神经变性疾病的溶酶体功能障碍的潜在措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号